Myomo, Inc.
MYO NYSE Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2016βFY2025
What Myomo, Inc. does
No business description yet.
- Legal name
- MYOMO, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 9, 2026
- Accession Β· CIK
- 0001193125-26-098531
0001369290
Revenue and margins
Myomo, Inc. had $40.9M of revenue in fiscal 2025, up 25.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$16.3M in fiscal 2025, β39.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Myomo, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 10.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably Myomo, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $15.5M | $5.3M | $8.9M | $24.9M | $18.4M |
| Debt incl. finance leases | β | β | β | $11.2M | $11.2M |
| Debt / equity | β | β | β | 0.5x | 1.0x |
| Current ratio | 4.5x | 2.6x | 2.5x | 3.2x | 3.3x |
| Quick ratio | 4.3x | 2.2x | 2.2x | 2.9x | 2.9x |
| Total assets | $20.1M | $10.2M | $14.6M | $42.2M | $38.6M |
| Total liabilities | $4.7M | $3.8M | $5.6M | $17.5M | $27.2M |
| Shareholders' equity | $15.4M | $6.4M | $9.0M | $24.7M | $11.4M |
| Net debt (β = net cash) | β | β | β | β$13.6M | β$7.2M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 4 / 8 | 2 / 8 | 4 / 8 | 4 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 3 / 9 |
| Accruals ratio | β25.0% | β76.0% | β6.4% | β5.0% | β23.8% | β4.7% | β3.2% | β16.0% | β10.2% | β2.6% |
| Altman Z'' | β68.40 | 3.04 | β17.97 | β35.06 | β10.78 | β7.81 | β30.16 | β20.10 | β3.95 | β8.82 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.1M | $1.6M | $2.4M | $3.8M | $7.6M | $13.9M | $15.6M | $19.2M | $32.6M | $40.9M |
| Gross profit | $0.8M | $1.1M | $1.7M | $2.4M | $5.0M | $10.3M | $10.3M | $13.2M | $23.2M | $26.9M |
| Research and development | $1.1M | $1.8M | $1.8M | $1.7M | $1.7M | $2.6M | $2.5M | $2.6M | $4.8M | $6.9M |
| Operating income | β$3.3M | β$6.5M | β$10.5M | β$10.8M | β$10.5M | β$10.3M | β$10.7M | β$8.2M | β$6.2M | β$14.4M |
| Interest expense | β | β | β | $0.1M | $0.2M | β | β | β | β | β |
| Pretax income | β | β | β | β | β$11.6M | β$10.3M | β$10.7M | β$8.0M | β$5.8M | β$15.1M |
| Income tax | $0.0M | $0.0M | β | β | β | $0.1M | $0.1M | $0.2M | $0.4M | $0.5M |
| Net income | β$3.6M | β$12.1M | β$10.3M | β$10.7M | β$11.6M | β$10.4M | β$10.7M | β$8.1M | β$6.2M | β$15.6M |
| Net income to common | β$4.4M | β$12.7M | β$10.3M | β$11.5M | β$12.2M | β$11.0M | β$10.7M | β | β | β |
| Diluted EPS | β$4.13 | β$2.93 | β$25.18 | β$20.79 | β$3.67 | β$1.89 | β$1.52 | β$0.28 | β$0.16 | β$0.37 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.01B | 0.01B | 0.03B | 0.04B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | β$3.2M | β$6.2M | β$9.6M | β$10.3M | β$9.0M | β$9.5M | β$10.2M | β$6.2M | β$3.3M | β$14.5M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $0.1M | $0.0M | $0.3M | $0.1M | $0.1M | $1.4M | $1.7M |
| Free cash flow | β$3.2M | β$6.2M | β$9.7M | β$10.4M | β$9.1M | β$9.9M | β$10.3M | β$6.3M | β$4.7M | β$16.3M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M | $0.2M | $0.2M | $0.9M |
| Stock-based compensation | $0.1M | $0.3M | $0.8M | $0.9M | $0.6M | $1.1M | $1.2M | $1.1M | $0.9M | $2.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.8M | $13.0M | $6.5M | $4.5M | $12.2M | $15.5M | $5.3M | $8.9M | $24.9M | $18.4M |
| Total debt | β | β | β | $2.7M | β | β | β | β | $11.2M | $11.2M |
| Current assets | $1.1M | $13.8M | $7.9M | $6.1M | $14.4M | $19.1M | $9.2M | $13.7M | $32.8M | $27.6M |
| Current liabilities | $3.0M | $1.5M | $1.9M | $3.9M | $2.9M | $4.3M | $3.6M | $5.5M | $10.2M | $8.3M |
| Inventory | $0.1M | $0.2M | $0.3M | $0.4M | $0.7M | $0.8M | $1.4M | $1.8M | $3.2M | $3.1M |
| Property and equipment, net | $0.0M | $0.1M | $0.2M | $0.2M | $0.1M | $0.3M | $0.2M | $0.2M | $1.3M | $2.2M |
| Total assets | $1.7M | $14.0M | $8.3M | $6.6M | $14.7M | $20.1M | $10.2M | $14.6M | $42.2M | $38.6M |
| Total liabilities | $6.5M | $1.5M | $1.9M | $4.8M | $3.1M | $4.7M | $3.8M | $5.6M | $17.5M | $27.2M |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$17.5M | $12.4M | $6.4M | $6.4M | $11.6M | $15.4M | $6.4M | $9.0M | $24.7M | $11.4M |
| Margins | ||||||||||
| Gross margin | 74.4% | 67.6% | 70.2% | 63.0% | 65.7% | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| Operating margin | β296.8% | β420.0% | β430.8% | β281.3% | β138.5% | β74.1% | β68.6% | β42.8% | β19.1% | β35.2% |
| EBITDA margin | β296.1% | β419.3% | β427.9% | β278.8% | β137.1% | β73.1% | β67.4% | β41.9% | β18.4% | β33.1% |
| Net margin | β327.8% | β776.0% | β422.1% | β279.2% | β152.5% | β74.9% | β68.9% | β42.3% | β19.0% | β38.1% |
| FCF margin | β290.5% | β399.0% | β398.2% | β270.8% | β119.7% | β71.3% | β66.5% | β32.8% | β14.3% | β39.7% |
| Returns | ||||||||||
| Return on capital | β | β | β | β184.9% | β | β | β | β | β44.3% | β268.8% |
| Return on capital employed | 243.9% | β52.4% | β163.8% | β397.6% | β88.7% | β64.9% | β162.7% | β90.4% | β19.4% | β47.5% |
| Return on equity | β | β | β109.3% | β166.7% | β128.5% | β76.9% | β98.5% | β106.2% | β36.7% | β86.2% |
| Return on assets | β218.1% | β154.8% | β92.7% | β144.0% | β108.5% | β59.6% | β70.9% | β65.9% | β21.8% | β38.5% |
| Return on tangible equity | β | β101.7% | β160.5% | β179.1% | β105.8% | β71.5% | β168.6% | β90.6% | β25.0% | β136.6% |
| Growth | ||||||||||
| Revenue growth | β | 41.3% | 56.8% | 57.0% | 97.6% | 82.7% | 12.3% | 23.7% | 69.2% | 25.7% |
| Share count change | β | 307.0% | β90.5% | 35.2% | 501.3% | 75.1% | 20.9% | 318.3% | 28.0% | 10.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | 0.4x | β | β | β | β | 0.5x | 1.0x |
| Interest coverage | β | β | β | β95.0x | β48.0x | β | β | β | β | β |
| Current ratio | 0.4x | 9.3x | 4.2x | 1.6x | 5.0x | 4.5x | 2.6x | 2.5x | 3.2x | 3.3x |
| Quick ratio | 0.4x | 9.2x | 4.1x | 1.5x | 4.8x | 4.3x | 2.2x | 2.2x | 2.9x | 2.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.2% | 4.3% | 5.2% | 1.4% | 0.6% | 2.4% | 0.7% | 0.8% | 4.2% | 4.3% |
| Stock comp / revenue | 8.5% | 17.9% | 33.3% | 23.7% | 8.1% | 7.9% | 7.7% | 5.8% | 2.7% | 5.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 2.0 | 4.0 | 4.0 | 2.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | β68.4 | 3.0 | β18.0 | β35.1 | β10.8 | β7.8 | β30.2 | β20.1 | β4.0 | β8.8 |
| Accruals ratio | β25.0% | β76.0% | β6.4% | β5.0% | β23.8% | β4.7% | β3.2% | β16.0% | β10.2% | β2.6% |
Source: SEC EDGAR XBRL filings (CIK 0001369290). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.